Report: Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC TOC

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Figures
3.2 List of Tables
3.3 List of Boxes

4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5 Antibody Drug Targets by Molecular Function

5.1 Carboxypeptidase Activity Targets
5.2 Catalytic Activity Targets
5.3 Cell Adhesion Molecule Activity Targets
5.4 Chaperone Activity Targets
5.5 Chemokine Activity Targets
5.6 Cofactor Binding Targets
5.7 Complement Activity Targets
5.8 Cytokine Activity Targets
5.9 DNA Topoisomerase Activity Targets
5.10 Extracellular Matrix Structural Constituent Targets
5.11 G-protein Coupled Receptor Activity Targets
5.12 Growth Factor Activity Targets
5.13 Hormone Activity Targets
5.14 Hydrolase Activity Targets
5.15 Intracellular Ligand-gated Ion Channel Activity Targets
5.16 Metallopeptidase Activity Targets
5.17 MHC Class I Receptor Activity Targets
5.18 Molecular Function Unknown Targets
5.19 Oxidoreductase Activity Targets
5.20 Peptide Hormone Targets
5.21 Protease Inhibitor Activity Targets
5.22 Protein Binding Targets
5.23 Receptor Activity Targets
5.24 Receptor Binding Targets
5.25 Receptor Signaling Complex Scaffold Activity Targets
5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
5.27 RNA-directed DNA polymerase Activity Targets
5.28 Serine-type Peptidase Activity Targets
5.29 T Cell Receptor Activity Targets
5.30 Translation Regulator Activity Targets
5.31 Transmembrane Receptor Activity Targets
5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
5.33 Transporter Activity Targets
5.34 Unclassified Targets

6 Antibody Drugs Targeting Signaling Pathways

6.1 Alpha6 Beta4 Integrin Signaling Pathway
- 6.1.1 Description of Pathway
- 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.2 Androgen Receptor Signaling Pathway
- 6.2.1 Description of Pathway
- 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.3 B Cell Receptor Signaling Pathway
- 6.3.1 Description of Pathway
- 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.4 EGFR1 Signaling Pathway
- 6.4.1 Description of Pathway
- 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.5 IL-2 Signaling Pathway
- 6.5.1 Description of Pathway
- 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.6 IL-4 Signaling Pathway
- 6.6.1 Description of Pathway
- 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.7 IL-6 Signaling Pathway
- 6.7.1 Description of Pathway
- 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.8 Kit Receptor Signaling Pathway
- 6.8.1 Description of Pathway
- 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.9 Notch Signaling Pathway
- 6.9.1 Description of Pathway
- 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.10 T Cell Receptor Signaling Pathway
- 6.10.1 Description of Pathway
- 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.11 TGF-beta Receptor Signaling Pathway
- 6.11.1 Description of Pathway
- 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
6.12 TNF-alpha Signaling Pathway
- 6.12.1 Description of Pathway
- 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.13 Wnt Signaling Pathway
- 6.13.1 Description of Pathway
- 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7 Antibodies Targeting Cancer Stem Cells

8 Targets of Antibody Conjugates

9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

9.1 Anti-Angiogenesis
9.2 Apoptosis
9.3 Protein Kinase Inhibitors

10 Antibody Targets and Drugs by Cancer Indications

10.1 Basal Cell Cancer
10.2 Biliary Cancer
10.3 Bladder Cancer
10.4 Bone Cancer
10.5 Brain Cancer
10.6 Breast Cancer
10.7 Cervical Cancer
10.8 Cervical Dysplasia
10.9 Colorectal Cancer
10.10 Endometrial Cancer
10.11 Esophageal Cancer
10.12 Fallopian Tube Cancer
10.13 Gastrointestinal Cancers
10.14 Head and Neck Cancer
10.15 Leukemias
10.16 Liver Cancer
10.17 Lung Cancers
10.18 Lymphomas
10.19 Melanoma
10.20 Mesothelioma
10.21 Myelodysplastic syndrome
10.22 Myelomas
10.23 Nasopharyngeal Cancer
10.24 Oesophageal Cancer
10.25 Ovarian Cancer
10.26 Pancreatic Cancer
10.27 Peritoneal Cancer
10.28 Prostate Cancer
10.29 Renal Cancers
10.30 Sarcomas
10.31 Thyroid Cancer

11 Expression Profiles of Antibody Drug Targets

11.1 Human Tissues and Cancer Tissues
11.2 Cancer Lines and Cells

12 Lung cancer: An Introduction

12.1 Current Treatment Strategies
12.2 Disease Definition
12.3 Etiology & Pathophysiology
12.4 Prognosis
12.5 Epidemiology

13 Progress in Current Lung Cancer Treatment Strategies

13.1 Improvements Adding microtubule Inhibitor
13.2 Improvement of Disease Related Symptoms in Elderly Patients
13.3 Toxicity Profile Favored
13.4 A New Formula
13.5 Monotherapy?
13.6 Failed to Demonstrate a Survival Advantage
13.7 Reduction in Mortality Risk

14 Key Drug Strategies in Lung Cancer

14.1 Apoptosis
14.2 Antiangiogenesis and Antivascular Agents
- 14.2.1 EGFR and VEGFR as target
- 14.2.2 Immunotherapy

15 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

15.1 Grade 4 Adverse Events
15.2 No New Remarks
15.3 No Significant Effect on Overall Survival
15.4 Bristol Myers Squibb Entered into an Agreement
15.5 Many Uncertainties Remain
15.6 Development Terminated
15.7 Continuing Enrollment
15.8 Apoptotic Inducer
15.9 Fully-Human Monoclonal Antibody
15.10 Eagerly Awaiting Data
15.11 Mutations and Response
15.12 Statistically and Clinically Significant Survival Advantage
15.13 Anti-Idiotypic Monoclonal Antibody
15.14 Shift in the Development Focus
15.15 Sensitizer
15.16 Treatment in Earlier-Stage Cancer Could be More Effective
15.17 Discontinued Radiosensitizer
15.18 Improvement in Chemoradiotherapy
15.19 Progress on HDAC Inhibitor
15.20 Progress Analysis Carboxyamidotriazole
15.22 Chemotherapy naïve subjects

16 Etiology and Pathophysiology of Melanoma

17 Current Melanoma Treatment Strategies

17.1 An Overview
17.2 Cytotoxic Drugs
- 17.2.1 Dacarbazine
- 17.2.2 Cisplatin
- 17.2.3 Carboplatin
- 17.2.4 Carmustine
- 17.2.5 Melphalan
- 17.2.6 Paclitaxel
- 17.2.7 Tamoxifen
- 17.2.8 Temozolomide
- 17.2.9 Vinblastine/Vinorelbine
- 17.3 Biological treatments
- 17.3.1 Intron A
- 17.3.2 Virulizin
- 17.3.3 Melacine
- 17.3.4 Alfanative (Multiferon)
- 17.3.5 Proleukin or (Macrolin)
- 17.3.6 Enhanzyn
- 17.3.7 M-VAX
17.4 Other
- 17.4.1 Ceplene Maxamine

18 Key Melanoma Therapy Strategies

18.1 Immunotherapy
18.2 Anti-angiogenesis
18.3 Apoptotic Induction
18.4 Gene Therapy

19 Current Melanoma Drug Development: Late Stage Pipeline

19.1 Immunotherapy
- 19.1.1 Oncophage
- 19.1.2 Canvaxin
- 19.1.3 GMK
- 19.1.4 MDX-010
- 19.1.5 OncoVax
- 19.1.6 ALLOVECTIN-7
- 19.1.7 Peginterferon alfa-2b
19.2 Anti-angiogenesis
- 19.2.1 Lenalidomide
19.3 Apoptotic Inducers
- 19.3.1 Genasense
19.4 Inhibiting Cell Growth
- 19.4.1 Temozolomide

20 Current Melanoma Drug Development: Early Stage Pipeline

20.1 Immunotherapy
- 20.1.1 INGN 241
- 20.1.2 QS-21
- 20.1.3 Talabostat
- 20.1.4 SB 249553
- 20.1.5 GVAX
- 20.1.6 GV 1001
- 20.1.7 Dexosome
- 20.1.8 Uvidem
- 20.1.9 NY-ESO-1 ISCOMS
- 20.1.10 NOVOVAC-M1
- 20.1.11 Oxxon Vaccine
- 20.1.12 Therion' s Melanoma Vaccine
- 20.1.13 ImmunoVex trimelan
- 20.1.14 OncoVEXGM-CSF
- 20.1.15 Zadaxin
- 20.1.16 Alvac-Mage1/Mage3
- 20.1.17 Iboctadekin
- 20.1.18 ProMune
- 20.1.19 BAY 504798
- 20.1.20 EMD 273063
20.2 Antiangiogenesis
- 20.2.1 Sorafenib
- 20.2.2 Vitaxin
- 20.2.3 Avastin
- 20.2.4 PI 88
20.3 Apoptotic Inducers
- 20.3.1 Didemnin B
- 20.3.2 KOS 953
20.4 Small Molecules Inhibiting Cell Growth
- 20.4.1 Pivanex
- 20.4.2 Karenitecin
- 20.4.3 Lomeguatrib
- 20.4.4 PD 0325901
- 20.4.5 SB 715992
- 20.4.6 INO 1001
- 20.4.7 CP 4055
20.5 Other Biological Drugs
- 20.5.1 AP 12009
- 20.5.2 Ecromeximab
- 20.5.3 ILX 651
- 20.5.4 Kahalalide F
- 20.5.5 ABX MA1
- 20.5.6 MJV 101
- 20.5.7 A Russian Melanoma Vaccine
- 20.5.8 Elea Vaccine
- 20.5.9 F 50040

21 Disclaimer

22 Appendix 1: Antibody Targets by Companies

23 Appendix 2. Treatment Guide Lines*

23.1 References

24 Appendix 3: Selected Company Profiles

24.1 Abgenix
24.2 Aphton
24.3 AstraZeneca
24.4 Bristol-Myers Squibb
24.5 Eli Lilly
24.6 Genentech
24.7 Genta
24.8 GlaxoSmithKline
24.9 ImClone
24.10 ISIS Pharmaceuticals
24.11 Ligand Pharmaceuticals
24.12 OSI Pharmaceuticals
24.13 Pfizer
24.14 Pharmacyclics
24.15 Sanofi- Aventis
24.16 Telik

25 Appendix 4 Progress profiles on approved drugs

25.1 Docetaxel
25.2 Vinorelbine
25.3 Gemcitabine
25.4 Paclitaxel
25.5 Pemetrexed
25.6 Gefitinib
25.7 Erlotinib

26 Appendix 4: Treatment Guide Lines Melanoma

27 Drug Index

28 Company Index

3.1 List of Figures

Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)
Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)
Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)
Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
Figure 6: Pipeline Maturation of Catalytic Activity Targets
Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target
Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets
Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target
Figure 10: Pipeline Maturation of Chaperone Activity Targets
Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target
Figure 12: Pipeline Maturation of Chemokine Activity Targets
Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target
Figure 14: Pipeline Maturation of Cofactor Binding Targets
Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target
Figure 16: Pipeline Maturation of Complement Activity Targets
Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target
Figure 18: Pipeline Maturation of Cytokine Activity Targets
Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target
Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets
Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target
Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets
Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target
Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets
Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target
Figure 26: Pipeline Maturation of Growth Factor Activity Targets
Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target
Figure 28: Pipeline Maturation of Hormone Activity Targets
Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target
Figure 30: Pipeline Maturation of Hydrolase Activity Targets
Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target
Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets
Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target
Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets
Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target63
Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets
Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target
Figure 38: Pipeline Maturation of Molecular Function Unknown Targets
Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target
Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets
Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target
Figure 42: Pipeline Maturation of Peptide Hormone Targets
Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target
Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets
Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target
Figure 46: Pipeline Maturationof Protein Binding Targets
Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target
Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)
Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)
Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)
Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)
Figure 52: Pipeline Maturationof Receptor Binding Targets
Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target
Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets
Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target
Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target
Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets
Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target
Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets
Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target
Figure 62: Pipeline Maturation of T cell Receptor Activity Targets
Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target
Figure 64: Pipeline Maturation of Translation Regulator Activity Targets
Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target
Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets
Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target
Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target
Figure 70: Pipeline Maturation of Transporter Activity Targets
Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target
Figure 72: Pipeline Maturation of Unclassified Targets
Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target
Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology
Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets
Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target

3.2 List of Tables

Table 1: Molecular Functions versus Oncology Antibody Drug Targets
Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets
Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets
Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets
Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets
Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets
Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets
Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets
Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets
Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets
Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets
Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets
Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets
Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets
Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets
Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets
Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets
Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets
Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets
Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets
Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets
Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets
Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets
Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets
Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets87
Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets
Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets
Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets
Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets
Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets
Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets
Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets
Table 36: Antibody Drugs Targeting Signaling Pathways
Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets
Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway
Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway
Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway
Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway
Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway
Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway
Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway
Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway
Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway
Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway
Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway
Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway
Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway
Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway
Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway
Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway
Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway
Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway
Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway
Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway
Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway
Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway
Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway
Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway
Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors
Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal
Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target
Table 67: Immunoconjugated Antibody Pipeline According to Target
Table 68: Antibodies in Oncology Reported to Affect Angiogenesis
Table 69: Antibodies in Oncology Reported to Affect Apoptosis
Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures
Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors
Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage
Table 73: Antibody Pipeline by Targets in Basal Cell Cancer
Table 74: Antibody Pipeline by Targets in Biliary Cancer
Table 75: Antibody Pipeline by Targets in Bladder Cancer
Table 76: Antibody Pipeline by Targets in Bone Cancer
Table 77: Antibody Pipeline by Targets in Brain Cancer
Table 78: Antibody Pipeline by Targets in Breast Cancer
Table 79: Antibody Pipeline by Targets in Cervical Cancer
Table 80: Antibody Pipeline by Targets in Cervical Dysplasia
Table 81: Antibody Pipeline by Targets in Colorectal Cancer
Table 82: Antibody Pipeline by Targets in Endometrial Cancer
Table 83: Antibody Pipeline by Targets in Esophageal Cancer
Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer
Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers
Table 86: Antibody Pipeline by Targets in Head and Neck Cancer
Table 87: Antibody Pipeline by Targets in Leukemias
Table 88: Antibody Pipeline by Targets in Liver Cancer
Table 89: Antibody Pipeline by Targets in Lung Cancers
Table 90: Antibody Pipeline by Targets in Lymphomas
Table 91: Antibody Pipeline by Targets in Melanoma
Table 92: Antibody Pipeline by Targets in Mesothelioma
Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome
Table 94: Antibody Pipeline by Targets in Myelomas
Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer
Table 96: Antibody Pipeline by Targets in Oesophageal Cancer
Table 97: Antibody Pipeline by Targets in Ovarian Cancer
Table 98: Antibody Pipeline by Targets in Pancreatic Cancer
Table 99: Antibody Pipeline by Targets in Peritoneal Cancer
Table 100: Antibody Pipeline by Targets in Prostate Cancer
Table 101: Antibody Pipeline by Targets in Renal Cancers
Table 102: Antibody Pipeline by Targets in Sarcomas
Table 103: Antibody Pipeline by Targets in Thyroid Cancer
Table 104: Expression Profiles of Antibody Drug Targets in Oncology
Table 1: Chemotherapeutic drugs for treatment of NSCLC
Table 2. Near Term Approved Drugs for the Treatment of NSCLC
Table 3: Chemotherapy Drugs off Patent
Table 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Table 5: VTA agents under development
Table 6: EGFR or VEGFR inhibitors
Table 7: FMS-like tyrosine kinases and their Synonyms
Table 8: Fms-related Tyrosine Kinase Targets in Development
Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 10: Cancer immunotherapy strategies
Table 11: Recently presented studies Lapatinib
Table 12: Recently presented studies ZD-6474
Table 13: Recently presented studies vinflunine
Table 14: Recently presented studies Panitumumab
Table 15: Recently presented studies Genasense
Table 16: Recently presented studies cetuximab
Table 17: Recently presented studies bevacizumab
Table 18: Recently presented studies bexarotene
Table 19: Recently presented studies Xcytrin
Table 1: Critical Risk Factors for Development of Melanoma
Table 2: Definition and Description of Stages of Melanoma
Table 3: Prognosis of the 4 Stages of Malignant Melanoma
Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
Table 5: Progress Profile Dacarbazine
Table 6: Progress Profile Cisplatin
Table 7: Progress Profile Carboplatin
Table 8: Progress Profile Carmustine
Table 9: Progress Profile Melphalan
Table 10: Progress Profile Paclitaxel
Table 11: Progress Profile Tamoxifen
Table 12: Progress Profile Temozolomide
Table 13: Progress Profile Vinblastine/Vinorelbine
Table 14: Progress Profile Interferon alfa-2b
Table 15: Development Milestones- Virulizin
Table 16: Development Milestones - Melacine
Table 17: Development Milestones - Alfanative
Table 18: Development Milestones - Proleukin
Table 19: Deployed Strategies for Blocking Angiogenesis
Table 20: Phase III Randomized Studies of Melanoma Vaccines.
Table 21: Tumor antigen based vaccines
Table 22: In vivo Gene Therapy
Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
Table 24: Ex vivo gene therapy loading of antigen presenting cells
Table 25: Overview of Immunostimulants in Development based on Type
Table 26: Overview of Immuno-Biologicals
Table 27: Overview of Gene Therapy Drugs for Immunostimulation
Table 28: MDX-010' s Collaborative History and Landscape
Table 29: Anti-angiogenisis Drugs under Development
Table 30: Overview Apoptopic Inducer Drugs
Table 31: Overview of Small Molecule Drugs
Table 32: Selected Regulatory Progress of Sorafenib
Table 33: Selected Regulatory Progress of Didemin B
Table 34: Overview of Various Biological Drugs in Development for Melanoma

3.3 List of Boxes

Box 1: Quick facts on Docetaxel
Box 2: Scientific Data on Docetaxel
Box 3: Quick Facts - Vinorelbine
Box 4: Scientific Data on Vinorelbine
Box 5: Quick Facts - Gemcitabine
Box 6: Scientific Data on gemcitabine
Box 8: Quick Facts - pemetrexed
Box 7: Scientific Data on Pemetrexed
Box 9: Quick Facts - Gefitinib
Box 10: Scientific Data on Gefitinib
Box 11: Quick Facts - Erlotinib
Box 1: Quick Facts - Enhanzyn
Box 2: Quick Facts - M-VAX
Box 3: M-VAX - Business & Market Bakground
Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
Box 5: Introgen' s INGN 241 Shows Vaccine Properties
Box 6: Quick Facts - Oncophage
Box 7: Oncophage - Designation and Status
Box 8: Quick Facts - Canvaxin
Box 9: Canvaxin - Designation and Status
Box 10: CancerVax Milestone payment
Box 11: Quick Facts - GM2-KLH Vaccine
Box 12: Progenics Reaquires Rights to Vaccine
Box 13: Completed Melanoma Phase III trials
Box 14: Quick Facts - MDX-010
Box 15: Quick Facts -OncoVax
Box 16: Quick Facts - ALLOVECTIN-7
Box 17: Quick Facts - Peginterferon alfa-2b
Box 18: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
Box 19: Quick Facts - Lenalidomide
Box 20: Quick Facts - Oblimersen
Box 21: Quick Facts - Temozomide
Box 22: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
Box 23: Regulatory Progress
Box 24: Quick Facts - INGN 241
Box 25: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
Box 26: Quick Facts - QS-21
Box 27: Quick Facts - Talabostat
Box 28: Quick Facts - SB 249553
Box 29: Quick Facts - GVAX
Box 30: Agreement Japan Tobacco and Cell Genesys
Box 31: Predicted launch of GVAX
Box 32: Quick Facts - GV 1001
Box 33: Quick Facts - Dexosome
Box 34: Important Milestones and License Fees
Box 35: Quick Facts - Uvidem
Box 36: Agreements Between Sanofi-Aventis and IDM
Box 37: Quick Facts - NY-ESO-1 ISCOMS
Box 38: NY-ESO-1 and ISCOMATRIX
Box 39: Quick Facts - NovoVac-M1
Box 40: Quick Facts - Oxxon vaccine
Box 41: Quick Facts - Therion' s Melanoma Vaccine
Box 42: Quick Facts - ImmunoVEX trimelan
Box 43: Quick Facts - OncoVEX GM-CSF
Box 44: Quick Facts - ZADAXIN
Box 45: Developmental History Thymosin alpha1
Box 46: Quick Facts - Alvac-Mage1/Mage3
Box 47: Quick Facts - iboctadekin
Box 48: Quick Facts - PF-3512676
Box 49: Quick Facts - BAY-504798
Box 50: Quick Facts - EMD-273063
Box 51: Quick Facts - Sorefenib
Box 52: Quick Facts - Vitaxin
Box 53: Quick Facts . Bevacizumab
Box 54: Quick Facts - PI88
Box 55: Quick Facts - Didemnin B
Box 56: Quick Facts - KOS 953
Box 57: Quick Facts - Pivanex
Box 58: Quick Facts - Karenitecin
Box 59: Company Statement
Box 60: Quick Facts - Lomeguatrib
Box 61: Quick Facts - PD 0325901
Box 62: Quick Facts - SB 715992
Box 63: Quick Facts - INO 1001
Box 64: Quick Facts - CP 4055
Box 65: Quick Facts - AP 12009
Box 66: Quick Facts - Ecromeximab
Box 67: Quick Facts - ILX 651
Box 68: Quick Facts - Kahalalide F
Box 69: Quick Facts - ABX MA1
Box 70: Quick Facts - MJV 101
Box 71: Quick Facts - Russian Melanoma Vaccine
Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
Box 73: Quick Facts - F 50040
Box 74: KpOmpA Technology